Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

Matinas BioPharma received a notice from NYSE American on June 24, 2026, regarding non-compliance with continued listing standards due to insufficient stockholders' equity relative to accumulated losses. The company submitted a compliance plan and has been granted until October 2, 2027, to regain compliance. Failure to meet standards by the deadline could result in delisting proceedings.